Identifying cisplatin-induced kidney damage in paediatric oncology patients

Barton, Chris D, Pizer, Barry, Jones, Caroline, Oni, Louise ORCID: 0000-0002-1532-2390, Pirmohamed, Munir ORCID: 0000-0002-7534-7266 and Hawcutt, Daniel B ORCID: 0000-0002-8120-6507 (2018) Identifying cisplatin-induced kidney damage in paediatric oncology patients. PEDIATRIC NEPHROLOGY, 33 (9). pp. 1467-1474.

Access the full-text of this item by clicking on the Open Access link.

Official URL: http://dx.doi.org/10.1007/s00467-017-3765-6

Abstract

Cisplatin is one chemotherapeutic agent used to treat childhood cancer in numerous treatment protocols, including as a single agent. It is likely to remain in clinical use over the long term. However, cisplatin-related toxicities, including neurotoxicity and nephrotoxicity, are common, affecting treatment, day-to-day life and survival of such children. With one in 700 young adults having survived childhood cancer, patients who have completed chemotherapy that includes cisplatin can experience long-term morbidity due to treatment-related adverse reactions. A better understanding of these toxicities is essential to facilitate prevention, surveillance and management. This review article discusses the effect of cisplatin-induced nephrotoxicity (Cis-N) in children and considers the underlying mechanisms. We focus on clinical features and identification of Cis-N (e.g. investigations and biomarkers) and the importance of magnesium homeostasis and supplementation.

Item Type:	Article
Uncontrolled Keywords:	Cisplatin, Paediatrics, Oncology, Nephrotoxicity, Tubular toxicity, Magnesium
Depositing User:	Symplectic Admin
Date Deposited:	18 Jul 2017 08:43
Last Modified:	19 Jan 2023 06:59
DOI:	10.1007/s00467-017-3765-6
Open Access URL:	http://rdcu.be/vaCB
Related URLs:	Author Publisher
URI:	https://livrepository.liverpool.ac.uk/id/eprint/3008531